Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

Active:	Yes
Cancer Type:	Brain & Spinal Cord Tumor Hematopoietic Malignancies Lymphoma Unknown Primary	NCT ID:	NCT04947319
Trial Phases:	Phase II	Protocol IDs:	ONO-4059-09 (primary) NCI-2021-14196
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Ono Pharmaceutical Company Limited
NCI Full Details:	http://clinicaltrials.gov/show/NCT04947319

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens (methotrexate/
temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line
therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.